News Search Results
Apr 28, 2025, 14:35 ET Late-Breaking Research from SK Life Science Labs at AACR Annual Meeting Shows p300-Selective Degraders are Potent Growth Inhibitors in Models of Aggressive Prostate Cancers and Solid Tumors
Biopharmaceuticals Co., Ltd., a global biotech focused on the research, development, and commercialization of treatments for disorders of the central nervous system (CNS) and cancer, presented late-breaking research at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago.
More news about: SK Life Science Labs
Apr 28, 2025, 14:15 ET INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
oncology, diabetes, central nervous system ("CNS") disorders, and B-cell-mediated autoimmune diseases. The Company's product candidates include, among others, SC291 for the treatment of, inter alia, B-cell malignancies; SC379 for the treatment of certain CNS disorders; and SG299, which is part of
More news about: Pomerantz LLP
Apr 28, 2025, 13:43 ET ABRINT GLOBAL CONGRESS 2025: TECHENABLER MOSTRA PROTEÇÃO HÍBRIDA CONTRA OS ATAQUES DE NEGAÇÃO DE SERVIÇO DESTINADA A OPERADORAS E ISPS DE QUALQUER TAMANHO
Edimburgo, no Reino Unido, a Corero está sediada em Londres e listada nos mercados AIM da Bolsa de Valores de Londres (ticker: CNS) e US OTCQX Market (OTCQX: DDOSF). Para mais informações, visite www.corero.com ou
More news about: TechEnabler
Apr 28, 2025, 08:00 ET Celltrion to present six abstracts in inflammatory bowel disease (IBD) at 2025 Digestive Disease Week® (DDW)
NEUROLOGIC REACTIONS Agents that inhibit TNF have been associated with central nervous system (CNS) manifestation of systemic vasculitis, seizure and new onset or exacerbation of CNS demyelinating disorders, including multiple sclerosis and optic neuritis and peripheral demyelinating disorders,
More news about: Celltrion
Apr 27, 2025, 22:00 ET 2025 AACR | Abbisko Therapeutics Presents Late-Breaking Pre-clinical Research Results on ABSK112 (EGFR exon20ins), ABSK131 (PRMT5*MTA), and ABK-KRAS-1
G12C inhibitors. Abbisko presented the following posters at the 2025 AACR: Title1: Preclinical Evaluation of ABSK112, a Selective and CNS-penetrant Compound with Strong HER2 Inhibitory Activity for Treating HER2-Driven Solid Tumors Session Category: Late-Breaking Research:
More news about: Abbisko
Apr 27, 2025, 21:00 ET ImmVira Presented Clinical Results of Oncolytic Product MVR-C5252 Targeting Malignant Glioma via Convection-Enhanced Delivery at 2025 AACR Annual Meeting
in collaboration with Duke University, a renowned institution with expertise in oncolytic virotherapy, immunotherapy, and CNS treatments. Unlike the commonly used Ommaya reservoir, MVR-C5252 is delivered intracranially via convection-enhanced delivery ("CED"). This approach
More news about: ImmVira
Apr 25, 2025, 20:00 ET Innovent Announces NMPA Approval of Limertinib, a Third-generation EGFR TKI Collaborated with ASK Pharma, for the First-line Treatment of Lung Cancer
0.34–0.58; p < 0.0001). In patients with central nervous system (CNS) lesions at baseline, median CNS PFS was also significantly longer with limertinib (20.7 months vs. 7.1 months), corresponding to a 72% risk reduction for CNS progression or death (HR 0.28; 95% CI: 0.10–0.82; p = 0.0136),
More news about: Innovent Biologics
Apr 25, 2025, 10:16 ET Belay Diagnostics Announces US Commercial Launch of Summit™: Breakthrough CSF Testing for CNS Cancer Detection and Management
clinical validation encompassed 124 patients with primary and secondary CNS cancers across both common and rare phenotypes. Glioblastomas, gliomas, medulloblastomas, and astrocytomas were included for primary CNS cancers. For metastatic CNS cancers, cancers originating in the lung, breast, and diffuse large
More news about: Belay Diagnostics
Apr 24, 2025, 10:00 ET THE MULTIPLE SCLEROSIS ASSOCIATION OF AMERICA INVITES YOU TO THE 11TH IMPROVING LIVES BENEFIT IN SUPPORT OF THE MS COMMUNITY
SclerosisMultiple sclerosis (MS) is a disease of the central nervous system (CNS), which consists of the brain, optic nerves, and spinal cord. MS damages or destroys the protective covering (known as myelin) surrounding the nerves of the CNS and can potentially injure the nerves as well. This damage causes reduced
More news about: Multiple Sclerosis Association of America
Apr 24, 2025, 09:20 ET Suvoda and Greenphire Announce Completion of Merger
global clinical trial technology company specializing in complex, life-sustaining studies in therapeutic areas like oncology, central nervous system (CNS), and rare diseases. Founded in 2013 by experts in eClinical technologies, Suvoda empowers clinical trial professionals to manage the most urgent moments
More news about: Suvoda LLC; Greenphire
Apr 24, 2025, 08:00 ET Alcyone Therapeutics Announces Strategic Financing to Advance an Expanded Pipeline of Pediatric-Focused Precision Therapeutics for Severe Neurological Diseases
clinical-stage pipeline of precision CNS therapeutics with a program exhibiting promising safety and preliminary efficacy data and significant commercial potential as a first-in-class disease-modifying therapy." CLN-301 is one component of Alcyone's diversified portfolio of CNS therapeutics, which also includes
More news about: Alcyone Therapeutics
Apr 24, 2025, 07:00 ET Corero Named Finalist for the 2025 Joseph C. Belden Innovation Award
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial of service (DDoS) protection specialists, announced that it has been named a finalist for the 2025
More news about: Corero Network Security
Apr 24, 2025, 06:38 ET Dizal to Showcase Data in Hematologic Malignancies and Lung Cancer at ASCO 2025
developing them over the course of their disease. NSCLC patients whose disease progressed after 3rd generation EGFR TKI treatment often develop CNS metastasis and exhibit acquired EGFR resistance mutations. Preclinical data shows that DZD6008 demonstrates good safety
More news about: Dizal Pharmaceutical
Apr 23, 2025, 19:00 ET Argent BioPharma Enters Germany - Europe's Largest Market
regions. About Argent BioPharmaArgent BioPharma Ltd. (ASX: RGT) develops proprietary therapeutics targeting central nervous system (CNS) and autoimmune disorders using its Neuro-Immune Modulatory (NIM) platform. Lead assets include CannEpil®, CogniCann®, and CimetrA®, which are now entering
More news about: Argent BioPharma Ltd.
Apr 23, 2025, 16:15 ET Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma
component of the formulation. Warnings and Precautions Hemorrhage Serious or fatal hemorrhage events, including fatal CNS hemorrhages, associated with prolonged thrombocytopenia, have occurred with VYXEOS. The overall incidence (grade 1-5) of hemorrhagic events was 74% in
More news about: Jazz Pharmaceuticals plc
Apr 23, 2025, 10:28 ET Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting
for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with
More news about: Nuvalent, Inc.
Apr 23, 2025, 07:00 ET Corero Appoints Edison Group to Strengthen U.S. and International Investor Distribution
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial of service (DDoS) protection specialists, today announced the appointment of
More news about: Corero Network Security
Apr 22, 2025, 17:31 ET XADAGO/EQUFINA Set to Revolutionize Parkinson's Disease Treatment Landscape | DelveInsight
drug, XADAGO, as a sub licensee of Zambon, had entered into a definitive agreement with Supernus Pharmaceuticals under which Supernus would acquire the CNS portfolio of US WorldMeds, including the US rights to XADAGOIn November 2019, Eisai announced that it had
More news about: DelveInsight Business Research, LLP
Apr 22, 2025, 13:28 ET INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
oncology, diabetes, central nervous system ("CNS") disorders, and B-cell-mediated autoimmune diseases. The Company's product candidates include, among others, SC291 for the treatment of, inter alia, B-cell malignancies; SC379 for the treatment of certain CNS disorders; and SG299, which is part of
More news about: Pomerantz LLP
Apr 22, 2025, 07:48 ET GenrAb Completes $5.6 Million Financing to Accelerate Development of its Lead Antibody Therapy (TGM-010) and Expand Pipeline of Neuroprotective Candidates
vote of confidence in the novel biology driving GenrAb's innovative and disruptive technology, which has the potential to transform the treatment of CNS disorders to the great benefit of society." About GenrAb, Inc. GenrAb, Inc. is harnessing the power of adaptive human immunity
More news about: GenrAb
Apr 18, 2025, 10:00 ET LG CNS Partners with NYCEDC to Bring Advanced Technologies and EV Charging to Brooklyn Army Terminal
transformation, LG CNS is playing a crucial role in shaping the future of the city. This collaboration between NYC and LG CNS represents a significant investment in both infrastructure and technology, positioning the city at the forefront of the smart city revolution. Beyond EV infrastructure, LG CNS is committed
More news about: LG CNS
Apr 17, 2025, 10:00 ET Monument Therapeutics Announces Appointment of Robert Radie as Chair and Heather Preston to Advisory Board
Monument Therapeutics, a precision-neuroscience company focused on the development of innovative treatments for serious central nervous system disorders (CNS), today announced two key leadership appointments. Robert S. Radie (Bob) has been appointed Non-Executive Chair of the Board, effective immediately,
More news about: Monument Therapeutics
Apr 17, 2025, 08:28 ET Saol Therapeutics Announces Major Clinical Milestones Across Multiple Development Programs
GA, Dublin, Ireland, and Hamilton, Bermuda. Saol is focused on development activity in CNS disorders such as spasticity and pain management, and orphan diseases. Saol is committed to providing and advancing therapeutic options for patients
More news about: Saol Therapeutics
Apr 17, 2025, 07:00 ET Advania Iceland Selects Corero Network Security to Deliver Scalable DDoS Protection for Critical Infrastructure
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial of service (DDoS) protection specialists, announced a new partnership with Advania Iceland, part of Advania Group,
More news about: Corero Network Security
Apr 16, 2025, 23:53 ET Verkada Perluas Tim Kepemimpinan Asia Pasifik Untuk Semakin Mendorong Pertumbuhan Regional
integrator dan mitra saluran terkemuka di wilayah tersebut, termasuk Bluechip Infotech, Focus Digital Security Solutions, Field Solutions Holdings, LG CNS, dan Takachiho Koheki. Tentang VerkadaDirancang dengan mempertimbangkan kesederhanaan, enam lini produk Verkada -
More news about: Verkada